Seeking the most impactful platforms, technologies and teams to build a brighter future. I am a super fan of the companies where I serve on the Board of Directors.- Biotech, and life science leaders: Elephas, Emulate, OriBiotech, Refeyn, TelesisBio, Triumvira, Vestaron, Vizgen.- Digital Health & Technology: DNANexus, Outcomes4Me, OPT, Saama, Scitara, VieCure.Exited: Ultivue [Acquired by Vizgen]

Exited: Current Health [Acquired by BBY], NanoView [Acquired by Unchained Labs], Codex [NASDAQ: DNAY], DeepLens [Acquired by Paradigm]Previous Director Roles: Eleanor Health, EnPlusOne, Hawthorne Effect, Isolation Bio, Octave, SimBioSys, Syapse.

Led Northpond's Convergent Technology team investing broadly across automated lab, software for pharma and diagnostic development and next generation clinical care.

Served as Board Observer at 908 Devices (NASDAQ: MASS) during June 2020-December 2020 IPO.

Served as commercial lead for novel translational oncology technology in the biopharma market. In this role, I collaborated with the CEO, Board of Directors, and other executive leaders on sustainable and scalable commercial execution. I led a team of seasoned professions across organizational levels. Selected Achievements:• Spearheaded a rebranding initiative to blend corporate objectives, technology solutions, and innovation opportunities into core values and brand messaging that captured the company’s short- and long-term vision. • Analyzed the customer experience and championed the rollout of a customer-centric culture complete with the buildout of new customer portal, which resulted in a 200% increase in our renewal rate. • Established scorecards, KPIs, and performance metrics to assess and improve pipeline health, as well as drive velocity to ensure growth was aligned with the organization’s strategic plan. • Refined sales, account management, business development, and marketing strategies to focus on capturing and retaining key multimillion-dollar accounts.

Leveraging my experience in Commercialization and M&A, I established a reputation as a go-to Commercial Leader for companies and investors in the Boston technology ecosystem. I developed new market assessments, launched new products, crafted sales strategies, and delivered strategic M&A. I also supported investors and venture capitalists to diligence investments in the space.Selected Achievements:• Consulted with Mitra Biotech (before they launched as Farcast Biosciences) on business development strategy and execution, eventually closing my firm to join them.• Developed a global marketing strategy for a European-based breakthrough Biodiscovery and Dx platform. • Defined key applications and implemented the product development process for a protein characterization platform. • Led licensing negotiations for an innovative platform from Harvard School of Public Health. • Completed Single Molecule market assessment and due diligence opportunity for a high-value European Venture Fund.• Guided the sale of a B2B software business to a Fortune 100 company. • Served on the Investment Committee for Purple Arch Ventures.

Served as global leader in $1B Analytical Science and Lab Services division. Lead of global strategic marketing, platform and business development, and commercialization initiatives, as well as coached and mentored a team of up to 65 professionals across divisions and organizational levels. I built strategic partnerships and alliances, collaborated with senior leaders as a key member of the Core Leadership Team, Corporate Growth Board, and Executive Steering Committee, and guided sustainability efforts following an organizational turnaround. My role included the development of technology and product roadmaps with a focus on diversifying our portfolio as part of a long-term sustainability process. We launched products for life science, environmental, and food industries, and I played a critical part in financial planning, reporting, and analysis as we grew.Selected Achievements: • Spearheaded strategic transformation including Product launches, R&D portfolio management and M&A• Directed 15 product launches across multiple lines, including Chromatography, Materials Characterization, and Infrared, Atomic, and Mass Spectrometry, which addressed significant revenue value and potential in market opportunities. • Designed optimization improvements that increased our business vitality index from 16% to 20% in one year, and developing global teams and business models based on regional cultural competency, which yielded 10% growth. • Transformed marketing and lead generation to maximize the number of leads ready for conversion. • Acted as co-lead for innovation incubator for new portfolio of services, as well as sponsored growth incubator that yielded 12 new ideas in the first year. • Earned 2014 Chairman’s Award for entrepreneurial leadership and change management strategy.

Served as Bioscience divisional lead for acquisition and inorganic growth. Collaborated with the Corporate CFO and VP of Strategy & Business Development on opportunity identification and realization. Served as key member of Integration Office for 2010 acquisition of Millipore by Merck KgAa. After a successful integration, I moved to lead key strategic initiatives as the Director of Commercial Development, defining our organizational design and best practices. I also contributed to synergy planning, evaluated emerging market priorities, and founded incubators to improve our technology solutions as part of an effort to enhance commercialization efforts. Selected Achievements:• Defined KPIs to ensure consistency of performance across divisions following the integration of Millipore into the Merck brand. • Managed FuturePull strategic project, which included identifying innovation opportunities in defining epigenetic, synthetic biology, and single cell analysis roadmaps and acting as commercial lead in creating use cases.

Lead and manage M&A and strategic initiatives to achieve growth

As an Associate in JPMorgan's HealthCare Investment Banking Team, I developed strategic relationships with corporate clients in the life sciences and diagnostics, biotechnology, healthcare, pharmaceuticals, and private equity sectors. Most of my role included guiding clients through M&A processes, helping them identify opportunities with the best growth and ROI potential, and conducting cost-benefit analyses of various scenarios. I also prepared deliverables and reporting for Boards and C-suite executives, as well as negotiated and drafted bids, contracts, and memoranda.